US › Healthcare

Tempest Therapeutics Inc (TPST)

US · Healthcare · Biotechnology

$0.89+1.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-27.7M
Profit YoY
-155.0%
EPS
$-0.50
EPS estimate
$-0.28

EPS came in at -0.50 against a street estimate of -0.28 — a miss of 80.0%.

Key statistics

Market cap
$14.0M
Forward P/E
0.0
P/B
16.65
Book value
$0.06
EPS (TTM)
$-5.70
52-week high
$12.23
52-week low
$0.84
50-day MA
$1.19
200-day MA
$3.14
Beta
-1.68

Analyst view

Analysts rate Tempest Therapeutics Inc a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $11.00.

Shareholding

Insiders
31.78%
Institutions
26.29%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.46%
Geode Capital Management, LLC0.54%
Vanguard Fiduciary Trust Co0.43%
BlackRock Inc0.24%
FMR Inc0.21%
Sabby Management LLC0.11%
Northern Trust Corp0.09%
Dimensional Fund Advisors, Inc.0.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tempest Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.